$0.83
-0.01 (-1.63%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ONCY is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
15 interventional · 1 with posted results
Held by 5 tracked-famous managers (MARSHALL WACE, LLP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC) · FINRA short interest 7.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal CancerNCT07446322Overall Response Rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Bevacizumab, FOLFIRI, Pelareorep | Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer | 60 | 2027-08-30 | in 375 d | 2026-08-19 |
| A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and AtezolizumabNCT07280377Overall Response Rate (ORR) for Cohort 1, 2, 4, and 5Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel, Trifluridine Tipiracil, mFOLFIRINOX Treatment Regimen | Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma | 122 | 2027-07-30 | in 344 d | 2026-05-19 |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyNCT04215146results2025-01-16Overall Response RateRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: Paclitaxel, Avelumab · Biological: Pelareorep | Breast Cancer Metastatic | 48 | 2022-08-01actual | — | 2025-01-16 |
| A Window-of-opportunity Study of Pelareorep in Early Breast CancerNCT04102618To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with operable early breast cancer. CelTIL is a combined IHC-based score based on tumor cellularity and stromal TILs.Non-randomized · Open-label · Treatment | Early Phase 1 | Terminatedsponsor's stated reason: Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met. | Biological: Pelareorep · Drug: Letrozole, Atezolizumab, Trastuzumab | Breast Cancer | 26 | 2022-04-20actual | — | 2022-08-15 |
| Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaNCT02620423Determine the safety and DLTs of REOLYSIN® and chemotherapy (gemcitabine OR irinotecan OR 5FU) in combination with pembrolizumab in patients with advanced pancreatic adenocarcinoma who have progressed after (or did not tolerate) first line treatmentOpen-label · Treatment | Phase 1 | Completed | Biological: REOLYSIN® · Drug: Chemotherapy, Gemcitabine, Irinotecan, Leucovorin, 5-fluorouracil, Pembrolizumab | Pancreatic Adenocarcinoma | 11 | Mar 2018actual | — | 2018-09-13 |
| Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal CancerNCT01274624Dose limiting toxicity to define maximum tolerated dose and recommended Phase 2 doseOpen-label · Treatment | Phase 1 | Completed | Biological: REOLYSIN® · Drug: Irinotecan, Leucovorin, Fluorouracil (5-FU), Bevacizumab | KRAS Mutant Metastatic Colorectal Cancer | 36 | Feb 2018actual | — | 2018-12-19 |
| Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the BladderNCT02723838Incidence of Treatment-Emergent Adverse EventsOpen-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Company has reprioritized clinical plans to focus on later-stage studies. | Biological: REOLYSIN® · Drug: Gemcitabine, Cisplatin | Muscle-invasive Transitional Cell Carcinoma of the Bladder | 0 | 2017-09-30 | — | 2017-03-07 |
| Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR ActivationNCT00861627Determine the objective response rate (complete response (CR) + partial response (PR)) of the treatment regimen in the study populationOpen-label · Treatment | Phase 2 | Completed | Biological: REOLYSIN® · Drug: Carboplatin, Paclitaxel | Carcinoma, Non-small Cell Lung | 37 | Sep 2015actual | — | 2015-12-02 |
| Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic MelanomaNCT00984464Determine the antitumor effect in terms of objective response rates (i.e., partial response (PR) and complete response (CR) to treatment)Open-label · Treatment | Phase 2 | Completed | Biological: REOLYSIN · Drug: Carboplatin, Paclitaxel | Metastatic Melanoma | 14 | Feb 2014actual | — | 2015-04-10 |
| A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic AdenocarcinomaNCT00998322Determine the clinical benefit rate (Complete Response (CR) + Partial Response (PR) + Stable Disease (SD))in the study populationNon-randomized · Open-label · Treatment | Phase 2 | Completed | Biological: REOLYSIN · Drug: Gemcitabine | Metastatic Pancreatic Adenocarcinoma | 34 | Dec 2013actual | — | 2015-04-10 |
| A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the LungNCT00998192Objective response rate (complete response (CR) + partial response (PR)) of the treatment regimen in the study populationOpen-label · Treatment | Phase 2 | Completed | Biological: REOLYSIN · Drug: Paclitaxel, Carboplatin | Metastatic or Recurrent Squamous Cell Carcinoma of the Lung | 32 | Sep 2013actual | — | 2016-03-31 |
| Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck CancersNCT01166542Overall survivalRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: REOLYSIN · Drug: Carboplatin, Paclitaxel, Placebo | Carcinoma, Squamous Cell of the Head and Neck | 167 | Apr 2012actual | — | 2014-11-05 |
| Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck CarcinomaNCT00753038Determine the objective response rate (complete response (CR) + partial response (PR)) of the treatment regimen in the study populationOpen-label · Treatment | Phase 2 | Completed | Biological: REOLYSIN® · Drug: Carboplatin, Paclitaxel | Carcinoma, Squamous Cell of the Head and Neck | 14 | Jul 2011actual | — | 2014-11-04 |
| Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the LungNCT00503295Complete response (CR) and partial response (PR) as well as prolonged stabilization of disease (SD) will be considered indicative of response. RECIST criteria will be utilized to assess radiographic response.Open-label · Treatment | Phase 2 | Completed | Biological: REOLYSIN® | Osteosarcoma, Ewing Sarcoma Family Tumors, Malignant Fibrous Histiocytoma, Sarcoma, Synovial, Fibrosarcoma, Leiomyosarcoma | 53 | Feb 2011actual | — | 2014-10-02 |
| Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant GliomasNCT00528684determine the maximum tolerated doseOpen-label · Treatment | Phase 1 | Completed | Biological: REOLYSIN® | Malignant Glioma | 18 | Apr 2010actual | — | 2014-10-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19